262 related articles for article (PubMed ID: 25168677)
1. Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: a therapeutic implication.
Suh DH; Kim HS; Kim B; Song YS
Biochem Pharmacol; 2014 Nov; 92(1):43-54. PubMed ID: 25168677
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition.
Thibault B; Castells M; Delord JP; Couderc B
Cancer Metastasis Rev; 2014 Mar; 33(1):17-39. PubMed ID: 24357056
[TBL] [Abstract][Full Text] [Related]
3. Metabolic approaches to overcoming chemoresistance in ovarian cancer.
Suh DH; Kim MK; No JH; Chung HH; Song YS
Ann N Y Acad Sci; 2011 Jul; 1229():53-60. PubMed ID: 21793839
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function.
Martinez-Outschoorn U; Sotgia F; Lisanti MP
Semin Oncol; 2014 Apr; 41(2):195-216. PubMed ID: 24787293
[TBL] [Abstract][Full Text] [Related]
5. Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission.
Tyagi K; Mandal S; Roy A
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188563. PubMed ID: 33971276
[TBL] [Abstract][Full Text] [Related]
6. Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication.
Lee M; Yoon JH
World J Biol Chem; 2015 Aug; 6(3):148-61. PubMed ID: 26322173
[TBL] [Abstract][Full Text] [Related]
7. Pyruvate uptake is increased in highly invasive ovarian cancer cells under anoikis conditions for anaplerosis, mitochondrial function, and migration.
Caneba CA; Bellance N; Yang L; Pabst L; Nagrath D
Am J Physiol Endocrinol Metab; 2012 Oct; 303(8):E1036-52. PubMed ID: 22895781
[TBL] [Abstract][Full Text] [Related]
8. Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer.
Xu S; Yang Z; Jin P; Yang X; Li X; Wei X; Wang Y; Long S; Zhang T; Chen G; Sun C; Ma D; Gao Q
Mol Cancer Ther; 2018 Jun; 17(6):1291-1302. PubMed ID: 29545331
[TBL] [Abstract][Full Text] [Related]
9. Metabolic reprogramming: the emerging concept and associated therapeutic strategies.
Yoshida GJ
J Exp Clin Cancer Res; 2015 Oct; 34():111. PubMed ID: 26445347
[TBL] [Abstract][Full Text] [Related]
10. Stress-Adaptive Response in Ovarian Cancer Drug Resistance: Role of TRAP1 in Oxidative Metabolism-Driven Inflammation.
Amoroso MR; Matassa DS; Agliarulo I; Avolio R; Maddalena F; Condelli V; Landriscina M; Esposito F
Adv Protein Chem Struct Biol; 2017; 108():163-198. PubMed ID: 28427560
[TBL] [Abstract][Full Text] [Related]
11. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism.
Li SS; Ma J; Wong AST
J Gynecol Oncol; 2018 Mar; 29(2):e32. PubMed ID: 29468856
[TBL] [Abstract][Full Text] [Related]
12. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells.
Han Z; Feng J; Hong Z; Chen L; Li W; Liao S; Wang X; Ji T; Wang S; Ma D; Chen G; Gao Q
Biochem Biophys Res Commun; 2013 May; 435(2):188-94. PubMed ID: 23665025
[TBL] [Abstract][Full Text] [Related]
13. Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells.
Dar S; Chhina J; Mert I; Chitale D; Buekers T; Kaur H; Giri S; Munkarah A; Rattan R
Sci Rep; 2017 Aug; 7(1):8760. PubMed ID: 28821788
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
15. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.
Pavlides S; Whitaker-Menezes D; Castello-Cros R; Flomenberg N; Witkiewicz AK; Frank PG; Casimiro MC; Wang C; Fortina P; Addya S; Pestell RG; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Cell Cycle; 2009 Dec; 8(23):3984-4001. PubMed ID: 19923890
[TBL] [Abstract][Full Text] [Related]
16. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.
Au Yeung CL; Co NN; Tsuruga T; Yeung TL; Kwan SY; Leung CS; Li Y; Lu ES; Kwan K; Wong KK; Schmandt R; Lu KH; Mok SC
Nat Commun; 2016 Mar; 7():11150. PubMed ID: 27021436
[TBL] [Abstract][Full Text] [Related]
17. Adipocyte pyroptosis occurs in omental tumor microenvironment and is associated with chemoresistance of ovarian cancer.
Lin CN; Liang YL; Tsai HF; Wu PY; Huang LY; Lin YH; Kang CY; Yao CL; Shen MR; Hsu KF
J Biomed Sci; 2024 Jun; 31(1):62. PubMed ID: 38862973
[TBL] [Abstract][Full Text] [Related]
18. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.
Kim A; Serada S; Enomoto T; Naka T
Expert Opin Ther Targets; 2010 Sep; 14(9):963-71. PubMed ID: 20673185
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
[TBL] [Abstract][Full Text] [Related]
20. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
